BeOne Medicines (ONC) Short term Debt (2015 - 2026)

BeOne Medicines (ONC) has reported Short term Debt for 11 consecutive years, with $116.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short term Debt fell 84.79% year-over-year to $116.1 million; the TTM figure through Mar 2026 stood at $116.1 million (down 84.79% YoY), while the FY2025 annual figure was $57.3 million, down 93.27% from the prior year.
• Short term Debt climbed to $116.1 million in Q1 2026 per ONC's latest filing, from $57.3 million in the prior quarter.
• Across five years, Short term Debt topped out at $863.8 million in Q3 2024 and bottomed at $50.0 million in Q4 2022.
• Historically, Short term Debt has averaged $481.8 million across 5 years, with a median of $421.1 million in 2023.
• Annual changes were most pronounced in 2023 — Short term Debt soared 1276.73% — and 2025, when it tumbled 93.95%.
• BeOne Medicines' Short term Debt stood at $50.0 million in 2022, then jumped by 1276.73% to $688.4 million in 2023, then gained by 23.7% to $851.5 million in 2024, then tumbled by 93.27% to $57.3 million in 2025, then soared by 102.71% to $116.1 million in 2026.
• Business Quant data shows ONC's Short term Debt at $116.1 million in Q1 2026, $57.3 million in Q4 2025, and $52.2 million in Q3 2025.